Fig. 2: CG1/A2xCD3 activates T cells and lyses CG1/HLA-A2-expressing myeloid leukemia.
From: Immunotherapy targeting a leader sequence cathepsin G-derived peptide
U937-A2 AML cells (A–C), ML2 AML cells (D–F) and EM2 CML cells (G–I) were co-cultured with PBMC and CG1/A2xCD3 for 24 h. Addition of CG1/A2xCD3 led to T cell activation, as measured using flow cytometry staining for CD69 (A, D, G) and increased cytokine section (IFNg, IL-2, and TNF-a) (B, E, H) by T cells in comparison with control bispecific antibody. C, F, I CG1/A2xCD3 increased the killing of target myeloid leukemia calls in comparison with control bispecific antibody. ***p < 0.001.
